03-22-2012

Heptares Therapeutics announced that an operating company of Shire plc has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the ...

more

03-02-2012

arGEN-X announced that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire. Using its SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire ...

more

09-01-2011

Shire plc announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme® (imiglucerase). Study results are ...

more

08-30-2010

Shire plc announced that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an orphan medicine through the ...

more

07-17-2009

Shire plc announces it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type I Gaucher disease. Shire is working with the FDA to determine subsequent steps and timing ...

more

10-13-2008

Jerini AG and Shire Deutschland Investments GmbH have completed the strategic review of the assets and programs of Jerini AG, not related to Icatibant (Firazyr®), as referred to in the Offer Document published by Shire Deutschland Investments GmbH on August 13, 2008. The Jerini Supervisory ...

more

10-06-2008

Shire Limited announces that following the approval by shareholders at the Annual General Meeting on September 24, 2008, the Company has changed its name to Shire plc with effect from today. Shire plc's ticker symbols on the London Stock Exchange and NASDAQ and the ISIN numbers of the ...

more

Jerini AG for an equity purchase price of EUR 328 million

07-07-2008

Shire Limited, the global specialty biopharmaceutical company, announced that Maia Elfte Vermögensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German indirect subsidiary of Shire Limited, will launch a voluntary public takeover offer for shares in Jerini AG, the ...

more

10-18-2007

At the U.S. Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee meeting, the majority of members voted to recommend the use of phosphate binders, including Shire Pharmaceuticals' non-calcium FOSRENOL(R) (lanthanum carbonate), to treat hyperphosphatemia ...

more

First human cell line-derived erythropoietin research reported

06-20-2006

Effective treatment of anaemia in patients suffering from chronic kidney disease (CKD) is possible with the first erythropoietin product produced in a human cell line. DYNEPO® (epoetin delta), developed using innovative gene activation technology in a human cell line, corrects and maintains ...

more